MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Motor control"

  • 2025 International Congress

    Dose Optimization of Foslevodopa/Foscarbidopa: Post Hoc Analysis of Study Completers

    J. Aldred, M. Bouchard, D. Kern, P. Mir, L. Bergmann, R. Gupta, M. O'Meara, J. Samuelsson, B. Bergmans (Spokane, USA)

    Objective: To describe dose optimization, efficacy, and safety of foslevodopa/foscarbidopa (LDp/CDp) in patients with advanced Parkinson’s disease (PwaPD) who completed a 52-week open-label study. Background:…
  • 2025 International Congress

    Characterization of neuronal exosomes purified from plasma of Parkinson’s Disease Chilean patients

    V. Urbina, C. Aguilera, E. Larraechea, D. Sepulveda, R. Vidal (Santiago, Chile)

    Objective: The diagnosis of PD is usually late and has only palliative treatments that seek to slow the progression of motor symptoms. These characteristics make…
  • 2025 International Congress

    Automatic Intelligibility Rating in Parkinson’s Disease: A Multilingual Approach

    T. Thies, F. Dörr, A. König, N. Linz, M. Barbe, J. Orozco-Arroyave, J. Rusz, J. Tröger (Saarbrücken, Germany)

    Objective: To investigate the validity and robustness of an automatically generated intelligibility score in Parkinson’s disease (PD) across multiple languages. Background: 90% of people with…
  • 2025 International Congress

    Foscarbidopa/Foslevodopa Therapy Improves Continuous Duration of Good ON Time and Correlated With Quality of Life in People With Parkinson’s Disease

    M. Bouchard, R. Hauser, P. Odin, D. Kern, S. Isaacson, L. Bergmann, L. Harmer, J. Homola, R. Gupta, C. Yan, C. Carroll (North Chicago, USA)

    Objective: To assess the impact of foscarbidopa/foslevodopa (CDp/LDp) continuous subcutaneous infusion (CSCI) on longest consecutive duration of Good and Best ON time and association of…
  • 2025 International Congress

    Global Cognition Influences Non-Tremor Motor Decline in Parkinson’s Disease

    M. Gibbs, A. D'Souza, C. Sotirakis, T. Crawford, J. Fitzgerald, C. Antoniades (Oxford, United Kingdom)

    Objective: To explore the longitudinal association between global cognition and i) global motor, ii) tremor, and iii) non-tremor motor severity and progression. Background: Impaired voluntary movement…
  • 2025 International Congress

    Effect of Sensory Feedback Vibration Stimulation Using an In-Sole Foot Pressure Monitor on Gait

    K. Kakegawa, T. Matsuda, J. Ogawa, Y. Yamaguchi, K. Fujinawa (Bunkyo-ku, Tokyo, Japan)

    Objective: To investigate the effects of a sensory feedback vibration stimulation device that integrates an insole foot pressure sensor on gait. Background: Foot pressure during…
  • 2025 International Congress

    Impact of ND0612 on Levodopa-Induced Dyskinesia in Parkinson’s Disease: Post hoc Analyses From a Randomized, Active-Controlled Study

    A. Ellenbogen, R. Pahwa, J. Hernández-Vara, N. Lopes, J. Pereira, A. Espay (Farmington Hills, USA)

    Objective: To evaluate dyskinesia-related outcomes between optimized subcutaneously administered levodopa/carbidopa (ND0612) + immediate-release levodopa/carbidopa (IR-LD/CD) vs optimized oral IR-LD/CD in patients with Parkinson’s disease (PD).…
  • 2025 International Congress

    Effect of Virtual Rehabilitation Therapy on Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis

    F. Luna-Rangel, B. Gonzalez-Bedolla, C. Armengol-Garcia, D. Martinez-Ramirez (Monterrey, Mexico)

    Objective: To assess the efficacy of virtual rehabilitation therapy compared to conventional physical therapy in patients with Parkinson’s disease. Background: Rehabilitation is essential in managing…
  • 2025 International Congress

    A Novel Quantitative Assessment to Evaluate Functional Impairment in Parkinson’s Disease

    V. Vanchinathan, M. Farah, A. Singh, C. Zhang, N. Osei-Owusu, R. Desai, R. Palani, J. Hamkins, M. Zwernemann, S. Grill, A. Pantelyat, J. Brašić (Baltimore, USA)

    Objective: To investigate if motion data collected from inertial measurement units (IMUs) mounted on implements used in activities of daily living (ADLs) can characterize the…
  • 2025 International Congress

    Opicapone in Parkinson’s Patients with Probable REM Sleep Behavior Disorder: Insights from the OASIS Trial

    J. Ferreira, M. Gago, R. Costa, M. Fonseca, H. Brigas, D. Magalhães, J. Holenz, C. Trenkwalder (Lisbon, Portugal)

    Objective: To evaluate opicapone’s effect on sleep disturbances, motor and non-motor symptoms and quality of life in Parkinson's disease (PD) patients with and without probable…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 45
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley